National Comprehensive Cancer Network
- NCCN
Guidelines®- End User License Agreement
- NCCN Guidelines for
Treatment of Cancer by Site- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Anal Carcinoma
- Basal and Squamous Cell Skin Cancers
- Bladder Cancer
- Bone Cancer
- Breast Cancer
- Central Nervous System Cancers
- Cervical Cancer
- Chronic Myelogenous Leukemia
- Colon Cancer
- Dermatofibrosarcoma Protuberans
- Esophageal and Esophagogastric Junction Cancers
- Gastric Cancer
- NCCN Guidelines for Detection,
Prevention, & Risk Reduction - NCCN Guidelines for
Supportive Care - NCCN Guidelines for
Age Related Recommendations - NCCN Guidelines for Patients®
- International Adaptations & Translations
- NCCN Pocket Guidelines
- NCCN Disclosure Policies &
Potential Conflicts of Interest - Licensing and Permissions
- Stay up-to-date with
NCCN Flash Updates™ - NCCN Guidelines Apps
- NCCN
Compendia- End User License Agreement
- NCCN Compendium®
- NCCN Biomarkers Compendium™
- Subscribe to the NCCN Compendia
- Licensing and Permissions
- Subscriptions
& Products- NCCN Compendium
- NCCN Biomarkers Compendium
- NCCN Templates
- Combination Subscriptions
- NCCN Flash Updates™
- NCCN Flash Updates™ Coupons
- NCCN Trends™ Surveys & Data
- NCCN Academy Video Modules
- NCCN eBulletin Newsletter
- NCCN Health Information Technology Licensees
- JNCCN — Journal of the National Comprehensive Cancer Network
- Advertising Opportunities
- NCCN Online Catalog
- Clinical & Business
Resources- Members Only
- NCCN Corporate Council
- NCCN Academy
- NCCN Insights: Analytics, Research & Consulting
- NCCN Resource Tool: REMS
- NCCN Collaboration with the National Business Group on Health
- NCCN Virtual Reimbursement Resource Room
- NCCN Health Information Technology Licensees
- NCCN Oncology Policy Program White Papers
- NCCN Oncology Research Program (ORP)
- ORP Recent News
- NCCN ORP Affiliate Research Project
- ORP Scientific Publications
- ORP Investigator Steering Committee
- ORP Testimonials
- Clinical Trials at NCCN Member Institutions
- Find ORP Funded Clinical Trials at NCCN Member Institutions
- NCCN Specialized Imaging Research Consortium™ (SIRC)
- NCCN ORP Disclosure Policy
- NCCN ORP for Industry
- NCCN Informed Consent Language Database
- NCCN Content Policies
- Patient
Resources- NCCN Guidelines for Patients®
- NCCN Website for Patients and
Caregivers - NCCN.com - Find an NCCN Member Institution
- Find an NCCN Cancer Center Near You
- Information on Patient Assistance & Reimbursement Help
- NCCN Virtual Reimbursement Resource Room Guide
- Find Clinical Trials
- NCCN Foundation
- Donate to the NCCN Foundation
NCCN Research & Business Resources
Trastuzumab Added to Esophageal and Gastric Cancer Guidelines
The NCCN Clinical Practice Guidelines in Oncology™ for Esophageal Cancer and the NCCN Clinical Practice Guidelines in Oncology™ for Gastric Cancer have been updated and published. Both Guidelines are now available in v.1.2010.
Trastuzumab in combination with systemic chemotherapy was added to the Esophageal and Gastric Cancer Guidelines as an option for the treatment of patients with advanced esophageal cancer, gastric cancer, or GE junction adenocarcinoma that is HER-2-positive as determined by a standardized method.
| Quick Links |
|
|
About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us
275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0260
Copyright © 2012 National Comprehensive Cancer Network, All Rights Reserved